FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* GOWEN MAXINE						2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS]								Check a	II applic Directo	able) r	g Pers	10% Ow	ner	
	LARIS THE	ERAPEUTICS, 1	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/03/2021									Officer below)	(give title		Other (s below)	pecify		
640 LEE ROAD, SUITE 200					4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) WAYNE	PA	A	19087			X Form filed by One Reporting Person Form filed by More than One Reporting Person														
(City)	(S	tate)	(Zip)																	
		Tab	ole I - Nor	ı-Deriv	ative	Se	curities	s Ac	quired,	Dis	posed o	f, or Be	nefici	ally O	wned					
Di Titto di Sossitti (ilistii s)				2. Transa Date (Month/E	saction //Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dis		Disposed	ecurities Acquired (A) osed Of (D) (Instr. 3, 4		and Securiti Benefic		es Fo ially (D) Following (I)		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(A) or (D) Pr		. Т	Transaction(s) (Instr. 3 and 4)				,iii3ti. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, T	ransaction Code (Instr.				6. Date Exercisa Expiration Date (Month/Day/Yea)	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		Deri Sec	3. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				c	code \	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amour or Number of Shares	er						
Stock Option (Right to Buy)	\$21.9	06/03/2021			A		12,250		(1)(2)	C	06/02/2031	Common Stock	12,25	0 \$	0.00	12,250		D		
Restricted Stock Units	(3)	06/03/2021			A		3,356		(1)(4)		(4)	Common Stock	3,350	5 \$	0.00	3,356		D		

- 1. This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy.
- 2. The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date.
- 3. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- 4. The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date.

Remarks:

/s/ Mark Ballantyne, Attorney-

06/04/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.